Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions. by Mbala-Kingebeni, Placide et al.
Mbala Kingebeni, Placide; Villabona-Arenas, Christian-Julian; Vi-
dal, Nicole; Likofata, Jacques; Nsio-Mbeta, Justus; Makiala-Mandanda,
Sheila; Mukadi, Daniel; Mukadi, Patrick; Kumakamba, Charles; Djokolo,
Bathe; Ayouba, Ahidjo; Delaporte, Eric; Peeters, Martine; Muyembe
Tamfum, Jean-Jacques; Ahuka Mundeke, Steve (2018) Rapid confir-
mation of the Zaire Ebola Virus in the outbreak of the Equateur
province in the Democratic Republic of Congo: implications for pub-
lic health interventions. Clinical Infectious Diseases, 68 (2). pp.
330-333. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciy527
Downloaded from: http://researchonline.lshtm.ac.uk/4650951/
DOI: 10.1093/cid/ciy527
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Clinical Infectious Diseases
330 • CID 2019:68 (15 January) • BRIEF REPORT
Rapid Confirmation of the Zaire Ebola 
Virus in the Outbreak of the Equateur 
Province in the Democratic Republic of 
Congo: Implications for Public Health 
Interventions
Placide Mbala-Kingebeni,1,2,3 Christian-Julian Villabona-Arenas,3  
Nicole Vidal,3  Jacques Likofata,4 Justus Nsio-Mbeta,5 Sheila Makiala-
Mandanda,1,2 Daniel Mukadi,1,2 Patrick Mukadi,1,2 Charles Kumakamba,1,6 
Bathe Djokolo,5 Ahidjo Ayouba,3 Eric Delaporte,3 Martine Peeters,3 Jean-
Jacques Muyembe Tamfum,1,2 and Steve Ahuka-Mundeke1,2
1National Institute of Biomedical Research, and 2Service de Microbiologie, Cliniques 
Universitaires de Kinshasa, Democratic Republic of Congo; 3Recherches translationelles sur 
le virus de l'immunodéficience et les maladies infectieuses, Institut de Recherche pour le 
Développement, University of Montpellier, Institut national de la santé et de la recherche 
médicale, France; and 4Laboratoire Provinciale, Mbandaka, and 5Direction Générale de Lutte 
contre la Maladie and 6Metabiota Inc., Kinshasa, Democratic Republic of Congo
Ten days after the declaration of the Ebola outbreak in the 
Democratic Republic of Congo, rapid identification of the 
species Zaire Ebola virus using partial gene amplification and 
nanopore sequencing backed up the use of the recombinant 
vesicular stomatitis virus–Zaire Ebola virus vaccine in the rec-
ommended ring vaccination strategy.
Keywords. Ebola; Democratic Republic of Congo; nanop-
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The Democratic Republic of Congo (DRC) declared a new out-
break of Ebola virus disease (EVD) on 8 May 2018. Initially, 
a report from the Provincial Health Division of the Equateur 
Province at the end of April informed the national authorities 
of 21 cases of potential hemorrhagic fever, including 17 deaths 
in the Ikoko-Impenge health area. Deployed disease experts on 
site identified 5 possible cases on 5 May and a blood sample was 
taken from each individual, 2 who were hospitalized in Bikoro 
and 3 at the health centre of Iboko. Samples were sent to Institut 
National de Recherche Biomédicale (INRB) in Kinshasa, and 
the presence of Ebola virus was identified in 2 samples on 7 May 
[1]. The samples tested positive with the OraQuick Ebola Rapid 
Antigen test (OraSure Technologies) and with the RealStar 
Zaire Ebolavirus reverse-transcription polymerase chain reac-
tion (PCR) kit 1.0 (Altona Diagnostics).
Proven emergency responses such as enhanced surveillance, 
active case finding, contact tracing, infection prevention, safe 
burials, and diagnosis with deployment of mobile laboratories 
on site were implemented rapidly. However, in 2017, the World 
Health Organization (WHO) recommended the deployment of 
the recombinant vesicular stomatitis virus–Zaire Ebola virus 
(rVSV-ZEBOV) candidate vaccine as an additional measure for 
prevention and control in the event of novel Zaire Ebola virus 
(EBOV) outbreaks [2]. This vaccine has been shown to be effect-
ive and safe and has been used during the epidemic decline of 
EBOV in Guinea in 2015 and during the flare-up of the dis-
ease in rural Guinea in 2016 [3, 4]. However, 4 species of Ebola 
viruses have been documented in Africa: Zaire (EBOV), Sudan 
(SUDV), Bundibugyo (BDBV), and Tai Forest [5]. Whereas 7 
of the 8 previous EBOV epidemics in DRC were due to EBOV, 
BDBV was responsible for the outbreak in Isiro in 2012, and pre-
vious outbreaks in South Sudan were all close to the border with 
DRC and were due to SUDV [6]. Therefore, it is thus important 
to confirm rapidly the viral strain of any new outbreak to guar-
antee the utility of anti-EBOV vaccination. Here, we describe the 
rapid laboratorial response that led to the confirmation of EBOV 
in the latest outbreak and highlight the implication of rapid viral 
detection for public health interventions.
MATERIALS AND METHODS
PCR Amplification
Viral RNA was extracted from 140 μL of whole blood collected 
from the 5 clinically suspected Ebola virus–infected individuals 
from Bikoro/Iboko using the Nuclisens kit (bioMérieux) and 
following the manufacturer’s instructions. After preparation 
of complementary DNA with GoScript Reverse Transcriptase 
(Promega, France), amplification of a small fragment of the 
VP35 region was attempted in a seminested PCR with a modified 
protocol adapted from He and colleagues [7]. Three additional 
samples were included as controls: 2 EBOV positive and 1 neg-
ative from the outbreak in Boende in 2014. In the first round, 
a 217-bp fragment was targeted with primers VP35-F: 5ʹ-AT-
YATGTATGATCACYTVCCWGG-3ʹ and VP35-R: AGCGR 
ATGTGGATSACRGGT-3ʹ. In the second round, an 184-bp 
product was amplified with primers VP35-R and VP35-in-F: 
5ʹ-GCTTTYCAYCAAYTAGTRCAAG-3ʹ.
Sequence Analysis
First-round VP35 PCR products from positive samples were 
barcoded and pooled using the Native Barcoding Kit (Oxford 
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Nanopore Technologies). Sequencing libraries were gener-
ated from the barcoded products using the Genomic DNA 
Sequencing Kit EXP-NBD103/SQK-LSK208 (Oxford Nanopore 
Technologies) and were loaded onto a R9 flow cell. Genetic data 
was collected for 1 hour.
Bioinformatics and Phylogenetic Analysis
Basecalling of sequenced data was done with ONT Albacore 
Sequencing Pipeline software version 2.1.10. Adapter removal 
and demultiplexing were achieved with Porechop 0.2.3.
Filovirus genus references were retrieved from the 
Hemorrhagic Fever Viruses (HFV) database at the Los Alamos 
National Laboratory. Multireference prealignment analysis of 
quality and error profiles using reads with basecall quality ≥11 
was done with the software package NanoOK 1.10. Ebola virus 
reads were corrected with Canu 1.6, and consensus sequences 
were produced by alignment of reads to the corresponding 
Ebola virus reference genome following signal-level analysis 
using Nanopolish 0.9.
One sequence per outbreak was retrieved from the HFV 
database and used for phylogenetic inference together with the 
nanopore consensus sequences. We also included a previously 
obtained VP35 sequence from an unpublished strain from the 
outbreak in Likati in 2017. Phylogenetic analyses were done 
using maximum likelihood methods with approximate like-
lihood ratio test nonparametric branch support based on a 
Shimodaira-Hasegawa–like procedure using PhyML version 
3.1 software. The HKY85 model plus a discrete gamma model 
were used as nucleotide substitution models.
RESULTS
The 2 positive control samples from Boende 2014 were suc-
cessfully amplified and no PCR product was obtained for the 
negative sample. The 2 samples from Bikoro/Iboko 2018 that 
tested initially positive with the commercial tests were also pos-
itive in the VP35 PCR, 2 other samples had a weak PCR prod-
uct, and the remaining sample resulted in no amplification. We 
attempted sequencing on the 6 samples with PCR amplifica-
tion. After 1 hour, between 400 and >4000 reads were obtained 
depending on the sample. NanoOK report indicated that >95% 
of the reads from the 2 known positive samples from Bikoro/
Iboko and the 2 positive control samples from Boende mapped 
to the EBOV species. The remaining reads and the reads from 
the samples with weak positive PCR product did not align to 
any filovirus genera and were queried in BLAST (Basic Local 
Alignment Search Tool), and the best hits pointed to human 
DNA. Consensus sequences were produced for the new EBOV 
strains and aligned with reference sequences from previous 
Ebola outbreaks including the 5 Ebola virus species and other 
filoviruses such as Marburg. The phylogenetic tree shown in 
Figure 1 underscores that this highly conserved region is dis-
criminatory between Ebola virus species and illustrates that the 
new strains from the ninth Ebola outbreak in DRC belong to 
the Ebola Zaire species (EBOV).
The laboratory results of the 5 suspected cases and the 
clinical signs and history for each patient are summarized in 
Supplementary Table  1. Overall, all 5 patients had diarrhea, 
severe fatigue, and abdominal pain. Additional symptoms were 
muscle or joint pain and anorexia for 4 of them. Three patients 
had also gum and/or nose bleeding among symptoms, but 
only 1 of them was confirmed as infected with Ebola virus by 
sequence and PCR analysis.
DISCUSSION
After only 10 days of the ninth Ebola outbreak declaration, the 
virus strain was confirmed as belonging to the Zaire species 
(EBOV). As in the outbreak in West Africa, nanopore sequenc-
ing using the MinION device proved useful for quick pathogen 
confirmation and strain identification [8, 9]. The device pro-
vided speed (library preparation, basecalling of preliminary 
read data and multireference prealignment took <6 hours) and 
ease of use besides portability advantages over other sequencing 
machines. The rapid viral characterization of the strain backed 
up the rVSV-ZEBOV candidate vaccine for the ring vaccina-
tion strategy recommended by WHO [2]. Today >1000 people 
have been vaccinated, mainly health professionals and people 
exposed to patients with confirmed EBOV and their contacts 
[1]. Nevertheless, further efforts to increase adequate hygiene 
practices and safe burials must also be continued.
Previous outbreaks in DRC were in very remote locations or 
small towns, but this new outbreak affected simultaneously at 
least 3 different locations in the Equateur Province. It included 
2 remote sites, Bikoro and Iboko/Itipo health areas, and cases in 
Mbandaka, a city of >1 million inhabitants and with transport 
and port links to the rest of the country and neighboring coun-
tries. The current outbreak is thus complex with the potential 
for urban and larger geographic spread. It was thus urgent to 
start rapidly the ring vaccination to stop the spread of the virus.
DRC had already experienced 8 other Ebola outbreaks since 
1976 [6]. The country has thus implemented a strategy at the 
national level to rapidly identify a potential new outbreak. 
This includes rapid reporting of clinical suspected cases and 
shipment of samples to the reference laboratory at INRB in 
Kinshasa for confirmation. In the current situation, the health 
service from Equateur Province gave the alert in late April. 
Nevertheless, the clinical presentations of the 5 suspected cases 
illustrate how difficult it is to distinguish Ebola from some other 
diseases without laboratory confirmation. A  similar alert was 
issued in February in the same area with 15 cases, among which 
8 individuals died, but no laboratory confirmation occurred 
(unpublished data). This observation underscores that the out-
break may have started earlier and emphasizes the potential of 
Ebola outbreaks to go unrecognized in remote areas. However, 
any relation between the 2 alerts remains to be examined.
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Each EVD outbreak is the result of a cross-species trans-
mission event from a reservoir or an intermediate/amplifying 
animal host species [6]. This new outbreak, together with the 
large outbreak in West Africa, illustrates the major conse-
quences of recurrent zoonotic spills. Studies on the ecology 
and animal reservoir of Ebola viruses are thus urgently needed 
so exposure to infection can be anticipated or avoided. Finally, 
the advantages provided by novel diagnostic technologies 
such as nanopore sequencing using the MinION device high-
light the importance of local capacity-building programs for 
rapid pathogen confirmation and corresponding public health 
interventions.
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